Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Behrens, Georg M NCossmann, Anne
Stankov, Metodi V
Schulte, Bianca
Streeck, Hendrik
Förster, Reinhold
Bosnjak, Berislav
Willenzon, Stefanie
Boeck, Anna-Lena
Thu Tran, Anh
Thiele, Thea
Graalmann, Theresa
Kayser, Moritz Z
Zychlinsky Scharff, Anna
Dopfer, Christian
Horke, Alexander
Pink, Isabell
Witte, Torsten
Wetzke, Martin
Ernst, Diana
Jablonka, Alexandra
Happle, Christine
Issue Date
2020-09-04
Metadata
Show full item recordAbstract
Background: Serology testing is explored for epidemiological research and to inform individuals after suspected infection. During the coronavirus disease 2019 (COVID-19) pandemic, frontline healthcare professionals (HCP) may be at particular risk for infection. No longitudinal data on functional seroconversion in HCP in regions with low COVID-19 prevalence and low pre-test probability exist. Methods: In a large German university hospital, we performed weekly questionnaire assessments and anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) measurements with various commercial tests, a novel surrogate virus neutralisation test, and a neutralisation assay using live SARS-CoV-2. Results: From baseline to week 6, 1080 screening measurements for anti-SARS CoV-2 (S1) IgG from 217 frontline HCP (65% female) were performed. Overall, 75.6% of HCP reported at least one symptom of respiratory infection. Self-perceived infection probability declined over time (from mean 20.1% at baseline to 12.4% in week 6, p < 0.001). In sera of convalescent patients with PCR-confirmed COVID-19, we measured high anti-SARS-CoV-2 IgG levels, obtained highly concordant results from enzyme-linked immunosorbent assays (ELISA) using e.g. the spike 1 (S1) protein domain and the nucleocapsid protein (NCP) as targets, and confirmed antiviral neutralisation. However, in HCP the cumulative incidence for anti-SARS-CoV-2 (S1) IgG was 1.86% for positive and 0.93% for equivocal positive results over the study period of 6 weeks. Except for one HCP, none of the eight initial positive results were confirmed by alternative serology tests or showed in vitro neutralisation against live SARS-CoV-2. The only true seroconversion occurred without symptoms and mounted strong functional humoral immunity. Thus, the confirmed cumulative incidence for neutralizing anti-SARS-CoV-2 IgG was 0.47%. Conclusion: When assessing anti-SARS-CoV-2 immune status in individuals with low pre-test probability, we suggest confirming positive results from single measurements by alternative serology tests or functional assays. Our data highlight the need for a methodical serology screening approach in regions with low SARS-CoV-2 infection rates.Citation
nfect Dis Ther. 2020 Sep 4:1–13. doi: 10.1007/s40121-020-00334-1. Epub ahead of print. PMID: 32886335.Affiliation
TWINCORE, Zentrum für experimentelle und klinische Infektionsforschung GmbH,Feodor-Lynen Str. 7, 30625 Hannover, Germany.Publisher
Springer HealthcareJournal
Infectious diseases and therapyPubMed ID
32886335Type
ArticleLanguage
enISSN
2193-8229ae974a485f413a2113503eed53cd6c53
10.1007/s40121-020-00334-1
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
Related articles
- Two-tiered SARS-CoV-2 seroconversion screening in the Netherlands and stability of nucleocapsid, spike protein domain 1 and neutralizing antibodies.
- Authors: Garritsen A, Scholzen A, van den Nieuwenhof DWA, Smits APF, Datema ES, van Galen LS, Kouwijzer MLCE
- Issue date: 2021 Jul
- SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic.
- Authors: Fuereder T, Berghoff AS, Heller G, Haslacher H, Perkmann T, Strassl R, Berger JM, Puhr HC, Kreminger J, Moik F, Schubert L, Starzer AM, Steindl A, Winkler S, Preusser M, Tobudic S
- Issue date: 2020 Sep
- Evaluation of 6 Commercial SARS-CoV-2 Serology Assays Detecting Different Antibodies for Clinical Testing and Serosurveillance.
- Authors: Nicholson S, Karapanagiotidis T, Khvorov A, Douros C, Mordant F, Bond K, Druce J, Williamson DA, Purcell D, Lewin SR, Sullivan S, Subbarao K, Catton M
- Issue date: 2021 Jul
- Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity.
- Authors: McAndrews KM, Dowlatshahi DP, Dai J, Becker LM, Hensel J, Snowden LM, Leveille JM, Brunner MR, Holden KW, Hopkins NS, Harris AM, Kumpati J, Whitt MA, Lee JJ, Ostrosky-Zeichner LL, Papanna R, LeBleu VS, Allison JP, Kalluri R
- Issue date: 2020 Sep 17
- A Cell-Based ELISA to Improve the Serological Analysis of Anti-SARS-CoV-2 IgG.
- Authors: Zarletti G, Tiberi M, De Molfetta V, Bossù M, Toppi E, Bossù P, Scapigliati G
- Issue date: 2020 Nov 8